logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 [see all tables in this series...]

Part (ii) Percentage amongst new clients with cocaine (HCl and crack) as primary drug

CountryInjectSmoke/inhaleEat/drinkSniffOthersBase (known status)Status unknown
Bulgaria0.00.00.0100.00.020
Czech Republic0.00.00.0100.00.010
Denmark1.89.10.988.20.011014
Germany11.723.21.557.56.214251436
Ireland0.64.20.095.20.01665
Greece2.428.62.466.70.0423
Spain(1)4.911.20.770.512.713257176
France7.727.50.062.02.814210
Italy6.263.40.030.40.092320
Cyprus7.132.10.060.70.0280
Latvia0.00.00.0100.00.020
Hungary4.56.86.881.80.0440
Malta12.115.20.072.70.0332
Netherlands(2)0.635.91.557.44.61343141
Slovakia0.00.00.050.050.020
Finland33.30.00.066.70.030
Sweden3.40.00.096.60.0291
United Kingdom(3)3.248.54.142.12.14485949
Total5.234.31.153.16.4303462737

Notes:

 Only countries where there are clients reported with cocaine (HCl and crack) as primary drug are shown. 

 (1) Data refer to 2004. 

 (2) Data refer to outpatient treatment centres and low-threshold agencies. 

 (3) Data refer to collection period between 01.04.2004 and 31.03.2005 

 See also 'Table TDI-110' for cocaine CIH and crack route of administration distribution, and 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

 2006 Reitox national reports - TDI - outpatient treatment centres. 

Page last updated: Monday, 12 November 2007